Nomura Asset Management
NTLA icon

Nomura Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Nomura Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,660
Closed -$186K – 1560
2022
Q1 		$266K Hold
3,660
– – ﹤0.01% 936
2021
Q4 		$433K Buy
+3,660
New +$459K ﹤0.01% 913

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Nomura Asset Management's NTLA Position: Q2 2022 in Review

Nomura Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 3,660 shares — an estimated $186K sold.

Nomura Asset Management first reported a position in NTLA in Q4 2021 and held it in 2 quarters. The position peaked at $433K in Q4 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Nomura Asset Management reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nomura Asset Management sold 3,660 Intellia Therapeutics shares in Q2 2022, an estimated $186K.
  • Nomura Asset Management first reported a position in Intellia Therapeutics in Q4 2021 and held it in 2 quarters.
  • Nomura Asset Management's Intellia Therapeutics position peaked at $433K in Q4 2021.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Nomura Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.